EODData

MEMBERSHIP REGISTER LOG IN

FRA, LDBA: H. LUNDBECK A/S SER.B DK1

05 Nov 2025
LAST:

6.120

CHANGE:
 0.04		OPEN:
6.120		HIGH:
6.120		ASK:
0.000		VOLUME:
760
CHG(%):
0.58		PREV:
6.085		LOW:
6.120		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Nov 256.1206.1206.1206.120760
04 Nov 256.0856.0856.0856.085760
03 Nov 256.3106.3106.3106.310760
31 Oct 256.3606.3606.3606.360760
30 Oct 256.3256.3256.3256.325760
29 Oct 256.1856.2756.1856.275760
28 Oct 256.0406.0406.0406.0401.5K
27 Oct 256.2056.2056.2056.2051.5K
24 Oct 256.2156.2156.2156.2151.5K
23 Oct 256.1206.1206.1206.1201.5K

COMPANY PROFILE

Name:H. LUNDBECK A/S SER.B DK1
About:H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. The company was founded in 1915 and is headquartered in Valby, Denmark.
Sector:Healthcare
Address:Ottiliavej 9, Valby, Denmark, 2500
Website:https://www.lundbeck.com
ISIN:DK0061804770

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:12.95 
Forward P/E:9.71 
PEG Ratio:0.53 
Price to Sales:0.25 
Price to Book:0.25 
Profit Margin:0.15 
Operating Margin:0.26 
Return on Assets:0.07 
Return on Equity:0.15 
DivYield:0.18 
Div/Share:0.95 
Revenue:3.147B 
EBITDA:644.69M 
Shares:792.43M 
Market Cap:4.85B 

TECHNICAL INDICATORS

MA5:6.242.0%
MA10:6.211.4%
MA20:6.160.7%
MA50:5.923.4%
MA100:5.3614.2%
MA200:5.1518.8%
STO9:25.00
STO14:25.00
RSI14:49.76
WPR14:-75.00
MTM14:-0.03
ROC14:0.00 
ATR:0.08 
Week High:6.363.9%
Week Low:6.090.6%
Month High:6.363.9%
Month Low:6.0418.8%
Year High:6.363.9%
Year Low:3.6866.2%
Volatility:4.31 

RECENT DIVIDENDS

Date Amount
27 Mar 2025$0.13
21 Mar 2024$0.09
22 Mar 2023$0.08